Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab in Diabetic Macular Edema
NCT02103283Phase 1Completed
- Sponsor
- Amgen
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of teprotumumab in diabetic macular edema (DME), sponsored by Amgen. Primary endpoint: Safety of RV001 at 9 weeks. Started Oct 2014; status: completed.
02
Drugs
teprotumumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT02103283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103283.